U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07466511) titled 'Effect of Bifidobacterium Breve Supplementation on the Onset and Progression of Idiopathic Scoliosis' on March 09.
Brief Summary: Researchers hypothesized that Bifidobacterium breve Supplement could reduce the progression rate of idiopathic scoliosis in children and potentially prevent the occurrence of new cases of scoliosis.
Study Start Date: Jan. 01, 2027
Study Type: INTERVENTIONAL
Condition:
Idiopathic Scoliosis
Intervention:
DIETARY_SUPPLEMENT: Bifidobacterium breve
Oral Bifidobacterium breve supplementation, 4.5 x 10^6 CFU daily for 6 months
BEHAVIORAL: Lifestyle Education
A standardized education session delivered a...